Together, our findings reveal a critical role for the SMYD3-MAP3K2 signaling axis in driving disease progression and aggressiveness in PCa and support continued investigation into the role of SMYD3 in additional models of PCa and its potential as a therapeutic target for metastatic disease. This evidence concerns the gene MAP3K2 and posterior cortical atrophy.